UW Madison UW School of Medicine and Public Health
UW Biiostatistics & Medical Informatics UW Biostatistics & Medical Informatics UW Madison UW Biostatistics & Medical Informatics Site Map

Biostatistics and Medical Informatics
Clinical Trials - Related Publications

The following is a list of clinical trials related publications (peer-reviewed) listed by research area.

Trial Design

    Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part I. Circulation 106:1015-1021, 2002.

    Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part II. Circulation 106:1172-1175, 2002.

    Chappell R, Miranpuri SS, Mehta MP. Dimension in defining tumor response (letter; comment). Journal of Clinical Oncology 16(3):1234, 1998.

    Cheung YK and Chappell R. Sequential designs for phase I clinical trials with late-onset toxicities. Biometrics 56:1177-82, 2000.

    DeGruttola VG, Clax P, DeMets DL, Downing GJ, Ellenberg SS, Friedman L, Gail MH, Prentice R, Wittes J, Zeger SL. Considerations in the evaluation of surrogate endpoints in clinical trials: summary of a National Institutes of Health workshop. Controlled Clinical Trials 22:485-502, 2001.

    DeMets, DL. Discussion [of paper: Changes in clinical trials mandated by the advent of meta-analysis, Statistics in Medicine 15:1263-68, 1996]. Statistics in Medicine 15: 1269-72, 1996.

    DeMets DL. Design of Phase II trials in congestive heart failure. American Heart Journal 139:S207-S210, 2000.

    DeMets DL. The role of surrogate outcome measures in evaluating medical devices. Surgery 128:379-385, 2000.

    DeMets DL. Clinical trials in the new millenium. Statistics in Medicine 19:2779-2787, 2002.

    DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part I. Circulation 106:746-751, 2002.

    DeMets DL, Califf RM. Lessons learned from recent cardiovascular clinical trials: Part II. Circulation 106:880-886, 2002.

    Douglas J. Item response models for quality of life in clinical trials. Statistics in Medicine 18:2917-31, 1999.

    Fleming TR, DeMets DL. Surrogate endpoints in clinical trials: Are we being mislead? Annals of Internal Medicine 125(7): 605-613, 1996.

    Fleming TR, DeGruttola V, DeMets DL. Surrogate endpoints. AIDS Clinical Research 1997-98:129-43.

    Jung SH, Carey M, Kim KM. Graphical search for two-stage designs for phase II clinical trials. Controlled Clinical Trials 22:367-72, 2001.

    Mehta M, Scrimger R, Mackie R, Paliwal B, Chappell R, Fowler J. A new approach to dose escalation in non-small-cell lung cancer. International Journal of Radiaion Oncology, Biology, and Physics 49:23-33, 2001.

    O'Shea JC, DeMets DL. Statistical issues relating to international differences in clinical trials. American Heart Journal 142:21-8, 2001.

    Pioro MH, Landefeld CS, Brennan PF, Daly B, Fortinsky RH, Kim U and Rosenthal GE. Outcomes-based trial of an inpatient nurse practitioner service for general medical patients. Journal of Evaluation in Clinical Practice 7(1):21-33, 2001.


    DeMets DL. Distinctions between fraud, bias, errors, misunderstanding, and incompetence. Controlled Clinical Trials 18:637-650, 1997.

    DeMets DL. Statistics and ethics in medical research. Science & Engineering Ethics 5(1):97-117, 1999.


Interim Monitoring
Statistical Methodology

    Chen YH, DeMets DL, Lan KK. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Controlled Clinical Trials 24:16-27, 2003.

    Cook TD. Adjusting survival analysis for the presence of unadjudicated study events. Controlled Clinical Trials 21:208-222, 2000.

    Cook TD. P-value adjustment in sequential clinical trials. Biometrics 58:1005-1011, 2002.

    Cook TD. Advanced statistics: up with odds ratios! A case for odds ratios when outcomes are common. Academic Emergency Medicine 9:1430-1434, 2002.

    Fine JP, Gelber RD. Joint regression analysis of survival and quality-adjusted survival. Biometrics 57:376-382, 2001.

    Fine JP, Tsiatis AA. Testing for differences in survival with delayed ascertainment. Biometrics 56:145-153, 2000.

    Gange SJ, DeMets DL. Sequential monitoring of clinical trials with correlated categorical responses. Biometrika 83(1):157-167, 1996.

    Gilbert PB, Wei LJ, Kosorok MR, Clemens JD. Simultaneous inferences on the contrast of two hazard functions with censored observtions. Biometrics 58:773-780, 2002.

    Gong J, Pinheiro JC, DeMets DL. Estimating significance level and power comparisons for testing multiple endpoints in clinical trials. Controlled Clinical Trials 21:313-329, 2000.

    Jiang H, Fine J, Chappell R. Estimation of the association between bivariate failure times in semi-competing risk problem. American Statistical Association Proceedings of the Biometrics Section 192-194, 1999.

    Kosorok MR. On global consistency of a bivariate survival estimator under univariate censoring. Statistics and Probability Letters 56:439-446, 2002.

    Kosorok MR, Lin CY. The versatility of function-indexed weighted log-rank statistics. Journal of the American Statistical Association 94:320-332, 1999.

    Lesaffre E, Spiessens B, Kim KM, Verbeke G. A group sequential method for logistic random-effects models. Controlled Clinical Trials 21:45S, 2000.

    Li Z, DeMets DL. On the bias of estimation of a Brownian motion drift following group sequential tests. Statistica Sinica 9(4): 923-937, 1999.

    Lin C-Y, Kosorok MR. A general class of function-indexed nonparametric tests for survival analysis. Annals of Statistics 27:1722-1744, 1999.

    Pan W, Chappell R. Estimating survival curves with left-truncated and interval-censored data under monotone hazards. Biometrics 54:1053-1060, 1998.

    Pan W, Chappell R. Estimation in the Cox proportional hazards model with left-truncated and interval-censored data. Biometrics 58:64-70, 2002.

    Qu RP, DeMets DL. Bias correction in group sequential analysis with correlated data. Statistica Sinica 9: 939-952, 1999.

    Reboussin DM, DeMets DL, Kim K, Lan KKG. Computations for group sequential boundaries using the Lan-DeMets methods. Controlled Clinical Trials 21:190-207, 2000.

    Spiessens B, Lesaffre E, Verbeke G, Kim KM, DeMets DL. An overview of group sequential methods in longitudinal clinical trials. Statistical Methods in Medical Research 9:497-515, 2000.

    Wei WH, Kosorok MR. Masking unmasked in the proportional hazards model. Biometrics 56:991-95, 2000.


Data Monitoring Committees

    DeMets DL. Pocock S, Julian DG: The agonising negative trend in monitoring clinical trials. Lancet 354: 1983-1988, 1999.

    DeMets DL. Commentary: Relationships between data monitoring committees. Controlled Clinical Trials 21: 54-55, 2000.

    DeMets DL and Yusuf S. The data and safety monitoring committee: some final thoughts. American Heart Journal 141(4):548-49, 2001.

    Fisher MR, Roecker EB, DeMets DL. The role of an independent statistical analysis center in the industry-modified National Institutes of Health model. Drug Information Journal 35:115-129, 2001.

    Fleming TR, Ellenberg S, DeMets DL. Monitoring clinical trials: issues and controversies regarding confidentiality. Statistics in Medicine 21:2843-2851, 2002.

    Freedman L, Anderson G, Kipnis V, Prentice R, Wang CY, Rossouw J, Wittes J, DeMets D. Approaches to monitoring the results of long-term disease prevention trials: examples from the Women's Health Initiative. Controlled Clinical Trials 17: 509-525, 1996.

    Lewis RJ, Berry DA, Cryer Henry III, Fost N, Krome, R, Washington GR, Houghton J, Blue JW, Bechhofer R, Cook T and Fisher M. Monitoring a clinical trial conducted under the FDA regulations allowing a waiver of prospective informed consent: The DCLHb Traumatic Hemorrhagic Shock Efficacy Trial. Annals of Emergency Medicine 38:4:397-404, 2001.

Final Results

    Auchter RM, Lamond JP, Alexander E, Buatti JM, Chappell R, Friedman W, Kinsella TJ, Levin AB, Noyes WR, Schultz C, Loeffler JS and Mehta MP: A multiinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. The International Journal of Radiation Oncology, Biology, and Physics 35: 27-31, 1996.

    Bonomi P, Kim K, Fairclough D, Cella D, Kugler J, Rowinski E, Jiroutek M, Johnson D. Comparison of survival and quality of life in advanced non-small cell lung cancer patients treated with paclitaxel-cisplatin versus etoposide-cisplatin: Results of an Eastern Cooperative Oncology Group trial. Journal of Clinical Oncology 18;623-631, 2000.

    Carbone P, Douglas J, Larson P, Verma A, Blair I, Pomplun M, Tutsch K. Phase I chemoprevention study of piroxicam and alpha-diflouromethylornithine. Cancer Epidemiology, Biomarkers, and Prevention 7:907-912, 1998.

    Chang AY, Kim K, Boucher H, Bonomi P, Stewart JA, Blum R. Randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in metastatic non-small cell lung cancer: An Eastern Cooperative Oncology Group study (EST 1587). Cancer 82:292-300, 1998.

    Gaynon PS, Qu RP, Chappell RJ, Willoughby ML, Tubergen DG, Steinherz PG, Trigg ME. Survival after relapse in childhood acute lymphoblastic leukemia: impact of site and time to first relapse the Children=s Cancer Group Experience. Cancer 82(7):1387-1395, 1998.

    Hotton KM, Khorsand M, Hank JA, Albertini M, Kim KM, Wilding G, Salamat MS, Larson M, Sondel P, Schiller JH. A phase Ib/II trial of granulocyte-macrophage-colony stimulating factor and interleukin-2 for renal cell carcinoma patients with pulmonary metastases: a case of fatal central nervous system thrombosis. Cancer 88:1892-1901, 2000.

    Johnson DH, Chang AY, Ettinger DS, Kim K, Bonomi P. Recent advances with chemotherapy in NSCLC: The ECOG experience. Oncology 12(1 Suppl 2):67-70, 1998.

    Lee AW, Foo W, Chappell R, Fowler JF, Sze WM, Poon YF, Law SC, Ng SH, O SK, Tung WY, Lau WH, Ho JH. Effect of time, dose, and fractionation on temporal lobe necrosis following radiotherapy for nasopharyngeal carcinoma. International Journal of Radiation Oncology, Biology, and Physics 40:35-42, 1998.

    Leu KM, Kim KM, Larson M, Schiller JH. Phase I/II trial of docetaxel and vinorelbine in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34:105-113, 2001.

    Loehrer PJ, Chen M, Kim K, Aisner SC, Einhorn LH, Livingston R, Johnson D. Cisplatin, doxorubicin and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma: An intergroup trial. Journal of Clinical Oncology 15:3093-3099, 1997.

    Love RR, Jacoby R, Newton MA, Tutsch KD, Simon K, Pomplun M, Verma AK. A randomized, placebo-controlled trial of low dose alpha-difluoromethylornithine in individuals at risk for colorectal cancer. Cancer Epidemiology, Biomarkers, and Prevention 7(11):989-992.

    Love RR, Duc NB, Havighurst TC, Mohsin SK, Zhang Q, DeMets DL, Allred DC. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. Journal of Clinical Oncology 21:453-457, 2003.

    Love RR, Duc NB, Allred DC, Binh NC, Dinh NV, Kha NN, Thuan TV, Mohsin SK, Roanh le D, Khang HX, Tran TL, Quy TT, Thuy NV, The PN, Cau TT, Tung ND, Huong DT, Quang le M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. Journal of Clinical Oncology 20:2559-2566, 2002.

    Love RR, Duc NB, Dinh NV, Shen TZ, Havighurst TC, Allred DC, DeMets DL. Mastectomy and oophorectomy by menstrual cycle phase in women with operable breast cancer. Journal of the National Cancer Institute 94:662-669, 2002.

    McGinn CJ, Junugi KA, Tutsch KD, Feierabend C, Alberti D, Lindstrom MJ, Wilding G, Arzoomanian RZ and Kinsella TJ. Leucovorin modulation of 5-iododeoxyuridine radiosensitization: a phase I study. Clinical Cancer Research 2:1299-1305, 1996.

    Merchant JJ, Kim K, Mehta MP, Ripple GH, Larson ML, Brophy DJ, Hammes LC, Schiller JH. Pilot and safety trial of carboplatin, paclitaxel, and thalidomide in advanced non-small cell lung cancer. Clinical Lung Cancer 2:48-52, 2000.

    Messing EM, Young TB, Hunt VB, Roecker EB, Vaillancourt AM, Crowley WP, Greenberg EB, Kuglitsch ME, Wegenke JD. Home screening for hematuria: Results of a multi-clinic study. Journal of Urology 148:289-292, 1992.

    Mundhenke C, Thomas JP, Wilding G, Lee FT, Kelzc F, Chappell R, Neider R, Sebree LA, Friedl A. Tissue examination to monitor antiangiogenic therapy: a phase I clinical trial with endostatin. Clinical Cancer Research 7:3366-74, 2001.

    Nelms BE, Mackie TR, Mackay JF, Hill CK, DeLuca PM, Lindstrom MJ, Deasy J, Gould MN: A comparison of cytotoxicity following whole vs. partial cell irradiation with synchrotron-produced ultrasoft x-rays. Radiation Research 150:521-527, 1998.

    Noyes WR, Rodriguez R, Knechtle SJ, Pirsch JD, Sollinger HW, D'Alessandro AM, Chappell R, Belzer FO, Kinsella TJ. Radiation therapy for renal transplant rejection refractory to pulse steroids and OKT3. International Journal of Radiation Oncology, Biology, and Physics 34:1055-1059, 1996.

    Roberts JA, Jenison EL, Kim K, Clarke-Pearson D, Langleben A. A randomized, multicenter, double-blind, placebo-controlled, dose-finding study of ORG 2766 in the prevention or delay of cisplatin-induced neuropathies in women with ovarian cancer. Gynecologic Oncology 67:172-177, 1997.

    Robles C, Kim KM, Oken MM, Bennett JM, Letendre L, Wiernik PH, O'Connell MJ, Cassileth PA. Low-dose cytarabine maintenance therapy vs observation after remission induction in advanced acute myeloid leukemia: an Eastern Cooperative Oncology Group Trial (E5483). Leukemia 14:1349-53, 2000.

    Sanghavi SN, Miranpuri SS, Chappell R, Buatti JM, Sneed PK, Suh JH, Regine WF, Weltman E, King VJ, Goetsch SJ, Breneman JC, Sperduto PW, Scott C, Mabanta S, Mehta MP. Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. International Journal of Radiation Oncology, Biology, and Physics 51:426-34, 2001.

    Steinherz PG, Gaynon PS, Breneman JC, Cherlow JM, Grossman NJ, Kersey JH, Johnstone HS, Sather HN, Trigg ME, Chappell R, Hammond D and Bleyer WA. Cytoreduction an dprognosis in acute lymphoblastic leukemia - the importance of early marrow response: report from the Children's Cancer Group. Journal of Clinical Oncology 14:389-398, 1996.

    Tester WJ, Kim K, Schiller JH, Krigel RL, Bonomi PD, Glick JH, Asbury RF, Kirkwood JM, Blum RH. A phase II study of recombinant Interleukin-2 with and without beta-Interferon for patients with advanced non-small cell lung cancer: An Eastern Cooperative Oncology Group study (PZ586). Lung Cancer 25:199-206, 1999.

    Turrisi AT, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, Wagner H, Aisner S, Johnson DH. Twice daily thoracic radiotherapy versus once daily thoracic radiotherapy in limited small cell lung cancer treated with concurrently with cisplatin etoposide chemotherapy. New England Journal of Medicine 340:265-271, 1999.

Final Results
    (listed alphabetically by first word)

    Executive Steering Committee on behalf of the SPORTIF III Investigators (includes DeMets, DL). Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomized controlled trial. The Lancet 362: 1691-98, 2003

    SPORTIF Executive Steering Committee for the SPORTIF V Investigators (includes DeMets, DL). Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation; a randomized trial. Journal of the American Medical Association 293:690-98, 2005.

    Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T, Carson P, DiCarlo L, DeMets D, White BG, DeVries DW, and Feldman AM. Cardiac-Resynchronization Therapy with or without and Implantable Defibrillator in Advanced Chronic Heart Failure. The New England Journal of Medicine 350: 2140-50, 2004.

    LaRosa, JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK for the Treating to New Targets Investigators (Fisher group). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. New England Journal of Medicine. 352:1425-35, 2005.

    O'Connor CM, Dunne MW, Pfeffer MA, Muhlestein JB, Yao L, Gupta S, Benner RJ, Fisher MR, Cook TD. Azithromycin for the secondary prevention of coronary hearth disease events. The WIZARD Study: A randomized controlled trial. Journal of the American Medical Association 290:1459-1466, 2003.



Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, Gottlieb SO, McGrew F, DeMets DL, White BG. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. New England Journal of Medicine 339:1810-1816, 1998.

Coumadin Aspirin Reinfarction Study (CARS) Investigators (includes DeMets DL, Fisher MR). Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 350: 389-396, 1997.

Langer A, Fisher M, Califf R, Goodman S, O'Connor C, Harrington R, Fuster V for the CARS Investigators: Higher rates of coronary angiography and revascularization following myocardial infarction may be associated with greater survival in the United States than in Canada. Canadian Journal of Cardiology 15:1095-1102, 1999.

MERIT-HF Study Group (includes DeMets DL): Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL randomised intervention triala in congestive heart failure (MERIT-HF). Lancet 353:2001-2007, 1999.

O'Connor CM, Carson PE, Miller AB, Pressler ML, Belkin RN, Neuberg GW, Frid DJ, Cropp AB, Anderson S, DeMets DL. Effect of amlodipine on mode of death among patients with advanced heart failure in the PRAISE trial. Prospective Randomized Amlopidine Survival Evaluation. American Journal of Cardiology 82:881-887, 1998.

O'Neill WW, Serruys P, Knudtson M, van Es GA, Timmis GC, van der Zwann C, Kleiman J, Gong J, Roecker EB, Dreiling R, Alexander J, Anders R. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. New England Journal of Medicine 342:1316-1324, 2000.

Packer M, Coats AJ, Fowler MB, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Castaigne A, Roecker EB, Schultz MK, DeMets DL. Effect of carvedilol on survival in severe chronic heart failure. New England Journal of Medicine 344:1651-1658, 2001.

Packer M, Fowler MB, Roecker EB, Coats AJ, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study. Circulation 106:2194-2199, 2002.

Packer M, O'Connor CM, Ghali JK, Pressler ML, Carson, PE, Belkin RN, Miller, AB, Neuberg GW, Frid D, Wertheimer JH, Cropp AB, DeMets DL for the Prospective Randomized Amlodipine Survival Evaluation Study Group. Effect of amlodipine on morbidity in severe chronic heart failure. New England Journal of Medicine 335(15):1107-1114, 1996.

Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, Konstam MA, Riegger G, Klinger GH, Neaton J, Sharma D, Thiyagarajan B on behalf of the ELITE II investigators (includes DeMets DL). Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355:1582-1587, 2000.

The Global Use of Strategies to Open Occluded Coronary Arteries in Acute Coronary Syndromes (GUSTO Iib) Angioplasty Substudy Investigators (includes DeMets DL): A clinical trial comparing primary coronary angioplasty with tissue plasminogen activator for acute myocardial infarction. New England Journal of Medicine 336(23): 1621-1628, 1997.

The International Steering Committee on Behalf of the MERIT-HF Study Group (includes DeMets DL): Rationale, design, and organization of the metoprolol CR/XL randomized intervention trial in heart failure (MERIT-HF). Amer J Cardiol 30(9B):54J-58J, 1997.

Cystic Fibrosis

Farrell PM, Kosorok MR, Rock MJ, Laxova A, Zeng L, Lai HC, Hoffman G, Laessig RH, Splaingard ML. Early diagnoses of cystic fibrosis through neonatal screening prevents severe malnutrition and improves long-term growth Wisconsin Cystic Fibrosis Neonatal Screening Study Group. Pediatrics 107:1-13, 2001.

Koscik RE, Kosorok MR, Farrell PM, Collins J, Peters ME, Laxova A, Green CG, Seng L, Rusakow LS, Hardie RC, Campbell PW, Gurney JW. The Wisconsin Cystic Fibrosis Chest Radiograph Scoring System: Validation and standardization for application to longitudinal studies. Pediatric Pulmonology 29:457-467, 2000.

Lai H-C, Kosorok MR, Laxova A, Davis LA, FitzSimmons SC, Farrell PM: Nutritional status of patients with cystic fibrosis with meconium ileus - a comparison with patients without meconium ileus and diagnosed early through neonatal screening. Pediatrics 105:53-61, 2000.

Lai H-C, FitzSimmons SC, Allen DB, Kosorok MR, Rosenstein BJ, Campbell PW, Farrell PM. Persistent growth impairment in children with cystic fibrosis following treatment with alternate-day prednisone. New England Journal of Medicine 342:851-859, 2000.

Bobadilla JL, Macek M Jr, Fine JP, Farrell PM. Cystic fibrosis: a worldwide analysis of CFTR mutations correlation with incidence data and application to screening. Human Mutation 19:575-606, 2002.


Pratt L, Waschbusch L, Ladd W, Gangnon R, Hendricks SK. Multiple vs. single betamethasone therapy. Neonatal and maternal effects. Journal of Reproductive Medicine 44(3):256-264, 1999.

Pridham KF, Kosorok MR, Greer F, Carey P, Kayata S, Sondel S. The effects of prescribed versus ad libitum feedings and formula caloric density of growing premature infants. Nursing Research 48:86-93, 1999.


Davis MD, Fisher MR, Gangnon RE, Barton F, Aiello LM, Chew EY, Ferris FL 3rd, Knatterud GL. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report: 18. Investigative Ophthalmology & Visual Science 39(2):233-252, 1998.


Sloan EP, Koenigsberg M, Gens D, Cipolle M, Runge J, Mallory MN, Rodman G Jr., for the DCLHb Traumatic Hemorrhagic Shock Study Group (includes Cook T, Fisher MR). Diaspirin Cross-Linked Hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock: A randomized controlled efficacy trial. JAMA 282:1857-1864, 1999.


Brennan PF. A computer network home care support demonstration: A randomized trial in persons living with AIDS. Computers in Biology and Medicine, 28:489-508, 1998.

Amyotrophic Lateral Sclerosis

ALS CNTF Treatment Study Group (includes Cook TD, DeMets DL, Fisher MR). A double blind placebo controlled clinical trial of subcutaneous recombinant ciliary neurotrophic factor (rHCNTF) in amyotrophic lateral sclerosis. Neurology 46:1244-1249, 1996.


Pirsch JD, D'Alessandro AM, Roecker EB, Knechtle SJ, Reed A, Sollinger HW, Kalayoglu M and Belzer FL. A controlled double blind randomized trial of verapamil and cyclosporine in cadaver renal transplant patients. American Journal of Kidney Diseases 21:189-195, 1993.

Rosenbek J, Roecker EB, Wood JL, Robbins J. Thermal application reduces the duration of stage transition in dysphagia after stroke. Dysphagia 11:225-223, 1996.

Zimmerman SW, Ahrens E, Johnson CA, Craig W, Leggett J, O'Brien M, Oxton L, Roecker EB, Engeseth S. Randomized, controlled trial of prophylactic rifampin for peritoneal dialysis related infection. American Journal of Kidney Disease 2:225-231, 1991.

UW Madison, Burton James Lab UW Madison, Commencement UW Madison, Chemical vials UW Madison, Bascom Hall UW Madison, Chapman Lab
Last Modified:
Copyright © 2014 Board of Regents - University of Wisconsin System